Researchers at ORNL are tackling a global water challenge with a unique material designed to target not one, but two toxic, heavy metal pollutants for simultaneous removal.
Oak Ridge National Laboratory’s Innovation Crossroads program welcomes six new science and technology innovators from across the United States to the sixth cohort.
To solve a long-standing puzzle about how long a neutron can “live” outside an atomic nucleus, physicists entertained a wild but testable theory positing the existence of a right-handed version of our left-handed universe.
Two decades in the making, a new flagship facility for nuclear physics opened on May 2, and scientists from the Department of Energy’s Oak Ridge National Laboratory have a hand in 10 of its first 34 experiments.
ORNL scientists will present new technologies available for licensing during the annual Technology Innovation Showcase. The event is 9 a.m. to 3 p.m. Thursday, June 16, at the Manufacturing Demonstration Facility at ORNL’s Hardin Valley campus.
More than 50 current employees and recent retirees from ORNL received Department of Energy Secretary’s Honor Awards from Secretary Jennifer Granholm in January as part of project teams spanning the national laboratory system. The annual awards recognized 21 teams and three individuals for service and contributions to DOE’s mission and to the benefit of the nation.
A world-leading researcher in solid electrolytes and sophisticated electron microscopy methods received Oak Ridge National Laboratory’s top science honor today for her work in developing new materials for batteries. The announcement was made during a livestreamed Director’s Awards event hosted by ORNL Director Thomas Zacharia.
As a medical isotope, thorium-228 has a lot of potential — and Oak Ridge National Laboratory produces a lot.
At the Department of Energy’s Oak Ridge National Laboratory, scientists use artificial intelligence, or AI, to accelerate the discovery and development of materials for energy and information technologies.
A rare isotope in high demand for treating cancer is now more available to pharmaceutical companies developing and testing new drugs.